Dead ringer

The biotech giant’s value leapt up to 40% after an Alzheimer’s treatment thought left for dead showed signs of life. The trick is to convince watchdogs to ignore the trials’ mixed results and the failure of similar drugs. But more tests, if not a return to the grave, are likely.